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Abstract 
The ability of melatonin treatment of aged animals to partially restore the pattern of gene 
expression characterizing the younger animal has been frequently reported.  The current 
study examines the effect of melatonin upon age-related changes of some key proteins 
relevant to the aging process.  These include glial fibrillary acidic protein (GFAP), NF-B, 
and protein disulfide isomerase (PDI).  In addition, overall neuronal status was examined by 
Nissl staining and evidence of apoptosis was sought with TUNEL staining.  Some age-related 
changes were in an upward direction (GFAP, NF-B and the extent of apoptosis as judged by 
the TUNEL method), while others were depressed with age (PDI and intensity of Nissl 
staining).  However, in either case, melatonin treatment of aged mice invariably altered 
these parameters so that they came to more closely resemble the levels found in younger 
animals.  The extent of this reversal to a more youthful profile, ranged from complete (for 
NF-B) to very minor (for Nissl staining and PDI). Overall, these findings are in accord with 
prior data on the effect of melatonin on cortical gene expression and confirm the value of 
melatonin as a means of retarding events associated with senescence. 
 
Keywords:  Brain aging; melatonin; inflammation; apoptosis; protein folding 
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1.  Introduction 
Aging is characterized by a progressive deterioration of physiological functions and 
metabolic processes.  In the aging brain, increased neuroinflammation is evidenced by 
higher steady-state levels of inflammatory cytokines and decreases in anti-inflammatory 
molecules (Sparkman and Johnson, 2008).  Elevated inflammatory responses in the aged 
brain can lead to increased neuronal death (Finch and Morgan, 2007, Marchalant et al., 
2008) and this may form a platform enabling the progression of neurodegenerative disease 
(Teeling and Perry, 2009).   
Melatonin (N-acetyl-5-methoxytryptamine) was discovered as a hormone of the pineal 
gland, but it is meanwhile known to be also synthesized in various other organs, tissues, and 
cells (Pandi-Perumal et al., 2006, Hardeland, 2008).  Since melatonin levels decline sharply 
with age, it has been hypothesized that the reduction of melatonin levels with age 
contributes to the aging process (Hardeland, 2012). The decline in melatonin production in 
aged individuals has been suggested as one of the primary contributing factors for the 
development of age-associated neurodegenerative diseases (Bondy and Sharman, 2010, 
Pandi-Perumal, 2012).  Melatonin is a multifunctional signaling molecule that has a variety 
of important functions. Numerous studies have shown that melatonin is efficient in 
preventing cell damage under both acute and chronic states. These include sepsis, asphyxia 
in newborns, neurodegenerative diseases, cancer and inflammation (Sharman and Bondy, 
2010, Sharman et al., 2011, Hardeland et al., 2011, Boga et al., 2012). 
___________________________________________________________________________  
Abbreviations:  GFAP =glial fibrillary acidic protein, PDI = Protein disulfide isomerase 
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This suggests a potential therapeutic use for melatonin in different fields of medicine.  We 
have previously shown that during senescence, there is a selective increase in mRNA levels 
of many genes associated with immune function. Such genes include those for several 
inflammatory cytokines. These age-related increases can be attenuated or even reversed by 
extended treatment with dietary melatonin (Bondy and Sharman, 2007, Sharman et al., 
2008). 
The current study sought to extend this work by examination of some proteins of the 
signaling pathways associated with the inflammatory cascade.  It was found that age 
related changes in GFAP and NFkB activity, were attenuated by melatonin and that several 
morphological events associated with senescence were also attenuated by prior melatonin 
administration.  Protein disulfide isomerase (PDI), is thought to be for reconstructing 
misfolded protein in endoplasmic reticulum lumen and since PDI has been identified as a link 
between misfolded protein and neuron apoptosis, this role may be important in protection 
against several neurodegenerative diseases (Hoffstrom et al., 2010, Andreu et al., 2012).  
Levels of PDI and intensity of Nissl staining in aged mice were found to be enhanced by 
treatment with dietary melatonin.  
 
2. Results 
Treatment of mice with melatonin in the diet did not alter rates of food consumption or 
accretion of body weight in either young or old mice. In accordance with several prior 
reports, GFAP levels were increased with age. GFAP was expressed in cortex and the 
hippocampus area of brain of all groups of mice (Fig. 1a).  However, in the globus pallidus, 
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GFAP stain was reduced staining after melatonin treatment (Fig. 1b). The proportion of 
astrocytes expressing GFAP can be considered as a marker of astroglial activation. 
Quantitative analysis revealed that GFAP levels were markedly elevated with age and that 
this was significantly attenuated by melatonin treatment (Figs 1c).  NF-B levels were also 
elevated in aged mice and were completely restored to younger levels in older animals 
treated with melatonin (Figs. 2a,b) 
Protein disulfide isomerase (PDI) was visualized using immunohistochemical procedures (Fig. 
3a) and staining intensity was quantitated (Fig. 3b).  PDI was strongly reduced in cortex 
with aging and this was reversed to a minor extent by the melatonin treatment.  
Nissl staining was used to visualize the regional density of cortical neurons, and was reduced 
in the globus pallidus of older mice relative to young animals.  This reduction was partially 
but not completely restored by melatonin treatment (Figs. 4 a, b). 
The terminal deoxynucleotidyl transferase-mediated digoxigenin-11-dUTP end labeling 
(TUNEL) method, labels fragmented DNA, which is a characteristic of the apoptotic cells. 
Little evidence of apoptotic cells was seen in the YC and YM groups, but TUNEL-positive cells 
were found in the cortex and hippocampus in both groups of older mice (Fig. 5a). 
Quantitative analysis revealed that apoptotic cells were more prevalent in the OC group 
than in the OM group (Fig. 5b).  
 
3. Discussion 
Aging involves a series of multifaceted and complex degradation processes whose overall 
effect is to gradually impair cellular and ultimately organismic efficiency. In the nervous 
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system, these include behavioral, and neuroendocrine changes, leading to progressive loss 
of ability to adapt effectively to the environment, and increased susceptibility to disease. 
Melatonin is an indole neuroendocrine hormone secreted by the pineal gland.  It was first 
isolated from bovine pineal gland and characterized by Lerner and his colleagues (Lerner et 
al., 1958). The amphiphilic nature of melatonin allows it to pass readily through hall 
biological membranes (Bonnefont-Rousselot and Collin, 2010).  Levels of melaton in plasma 
and in brain decline markedly with senescence (Lahiri et al., 2004).  However, application of 
exogenous melatonin by way of the diet can increase cortical levels of free unconjugated 
melatonin (Lahiri et al., 2004).  This may extend life expectancy, postpone aging, reducing 
the incidence of age-related diseases (Bondy and Sharman 2010, Tan et al., 2010).  The 
beneficial effects of melatonin have been variously attributed to its properties as an 
antioxidant, a modulator of apoptosis and a positive regulator of immune functions (Bondy 
and Sharman 2010, Korkmaz et al., 2012).  Melatonin treatment can partially reverse many 
of the increases in expression of genes related to inflammation that take place with aging 
(Sharman et al.,2007). This leads to a more youthful response to an inflammatory challenge 
(Perreau et al., 2007).  This influence on gene expression may underlie the many reported 
attributes of melatonin.  
We observed an effect of melatonin treatment on reducing basal GFAP levels in medial 
globus pallidus. This is in accord with our prior finding that GFAP mRNA expression is also 
elevated with age (Sharman et al., 2008). Not only is GFAP elevated with age but also its 
increase in response to brain injury is accentuated and prolonged. This may contribute to 
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the worse cognitive outcome encountered following traumatic brain injury in the elderly  
(Sandhir et al., 2008).  
The age-related increase in NF-κB immunoreactivity that occurred despite the presence of 
an exogenous stimulus, was attenuated by melatonin treatment.  In nervous tissue, NF-κB 
is not merely a pro-inflammatory species but also has an important role in regulation of 
neurogenesis and short-term spatial memory (Mattson, 2005)) and in neuroprotection from 
stressors (Yang et al., 2007). Since neurogenesis and short-term spatial memory are not 
improved with aging, inhibition of an age-related elevation of NF-B is likely to be beneficial 
rather than detrimental.  
The mammalian PDI (protein disulfide-isomerase) family encompasses several highly 
divergent proteins that are involved in the processing and maturation of secretory proteins 
in the endoplasmic reticulum by catalyzing the rearrangement of disulfide bonds. Most 
secretory and membrane proteins contain disulfide bonds that are required for their 
functions (Vekitch et al., 2012). Protein disulfide bond formation in the endoplasmic 
reticulum (ER) is also critical for a formation of the correct tertiary structure of proteins, 
enabling normal protein folding  (Lipton et al., 2007, Uehara et al., 2006). Such chaperone 
activities can have important implications for neurodegenerative processes (Andreu et al., 
2012).  PDI may help protect the brain tissue by inhibition of pro-inflammatory events 
(Zhou et al., 2008).  The dramatic age-related decrease in PDI that we observed may be a 
factor underlying the excess inflammation and accretion of proteinaceous deposits found in 
the senescent brain.  Melatonin effect a limited but significant amelioration of this decline, 
and this may have therapeutic relevance.  
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Melatonin was able to dramatically reduce the extent of apoptosis in aged mice to levels 
characteristic of younger mice.  Apoptosis is one of the more critical processes implicated 
in aging and neurodegenerative pathologies, (Caballero and Coto-Montes, 2012). Melatonin 
can readily enter subcellular structures, cells and body fluids due to its lipophilic and 
hydrophilic dual-polarity molecular character. This penetrance capability may account for its 
ability to xxx Overall, these findings give further evidence of the potentially protective role of 
melatonin in retarding the progression of several adverse events associated with 
senescence. 
 
4. Experimental Procedures   
4.1 Animal Treatment 
Male B6C3F1 mice, a hybrid between C57BL/6 and C3H from Harlan Labs (Indianapolis, IN), 
aged 5.5 months (young group) and 23.4 months (old group), were housed two to four per 
cage and were maintained on a 12 h light/dark cycle in a temperature controlled (22 ± 1°C) 
room. The B6C3F1 hybrid was used in order to take advantage of both the genetic and 
phenotypic uniformity and the vigor (increased disease resistance, better survival under 
stress and greater natural longevity) typical of hybrids.  Food and water were provided ad 
libitum. Young (YC) and old (OC) control animals were fed a pelleted minimal basal diet 
(AIN-93 M, #100900, Dyets Inc., Bethlehem, PA) consisting of 10% sucrose and 14% casein 
(w/w) as well as a minimal salt and vitamin mix. The basal diet of two similarly aged cohorts 
(YM and OM, respectively) was supplemented with 40-ppm (w/w) melatonin (Sigma, St. 
Louis, MO) for 9.3 weeks. Twelve mice were used in each experimental group. All 
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experiments were approved by the Institutional Animal Care and Use Committee at the 
University of California, Irvine, and conformed to the National Institute of Health guide for 
the care and use of laboratory animals.  
4.2 Tissue preparation 
Mice were deeply anesthetized with an overdose of pentobarbital (150 mg/kg, i.p.) and then 
transcardially perfused with cold phosphate-buffered saline (PBS). After dissection, one half 
of the brain fixed overnight with 4% p-formaldehyde in PBS, pH 7.4. Thereafter, fixed tissue 
was stored in PBS/0.02% sodium azide (NaN3) at 4°C until use. Finally, the fixed brain tissue 
was further processed by dehydration in a series of graded ethanol solutions prior to 
paraffin embedding. The blocks were cut in serial 5um thick sections and mounted on 
adhered slides pretreated with Vectabond reagent (Vector Laboratories, Burlinghame, CA, 
USA) in a water bath at 45°C. Tissue slides were stored at 4°C before being stained. 
4.3 Immunohistochemistry  
Sections were heated for 25 m at 56°C and then deparaffinized in a xylene bath followed by 
rehydration using a graded series of ethanol concentrations. Immunohistochemistry was 
then carried out after incubation for 20 m at 80°C with antigen unmasking solution (Vector 
Laboratories, Burlinghame, CA, USA).  Endogenous peroxidase in tissue was blocked by 
treatment with 3% H2O2 in PBS, for 20 m at 25°C. Non-specific background staining was 
blocked by a 2-h incubation in 2% bovine serum albumin with 0.3% Triton X-100. Sections 
were then incubated with primary antibodies (GFAP 1:1000 Dako Inc., Carpentaria, CA, USA), 
NFkB 1:200, PDI 1:500 Santa Cruz Biotechnology, Santa Cruz, CA, USA) overnight at 4°C, 
Sections were then rinsed in PBS with 0.1% Triton X-100, and incubated with biotinylated 
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secondary antibody (Vector Laboratories) and streptavidin–horseradish peroxidase (Jackson 
ImmunoResearch, West Grove, PA, USA) for 1h at 25°C.  Finally, the sections were 
incubated for 2–5 min with diamino-benzidine (Vector Laboratories). Sections dehydrated in 
a series of graded ethanol, cleared with xylene, and then cover-slipped with DePeX (BHD; 
Biomedical Specialties, Santa Monica, CA, USA).  As controls, sections were incubated in 
parallel without primary antibody in order to ascertain that these sections failed to develop 
specific staining. 
Sections were cut with a microtome at a range of 8 um, and put on microscope slides and 
after a rapid rehydration were placed in 1% Methylene Blue for 30 minutes.  Then the 
slides were dehydrated, put in xylene for 5 minutes, covered with Entellan resinous 
embedding agent (Merck, Whitehouse Station, NJ), cover-slipped and then images were 
captured with a Nikon Eclipse 200 photomicroscope. 
4.4 Nissl Staining 
Nissl staining of formaldehyde-fixed section was used to highlight important structural 
features of neurons.  This was caried out with Nissl stain solution consisting of 20mg each 
of cresyl violet acetate, toluidine and thionine per 100 ml solution.  0.3 ml glacial acetic 
acid was added to each 100 ml Nissl stain solution immediately prior to use. The Nissl 
substance (rough endoplasmic reticulum) appeared dark blue due to the staining of 
ribosomal RNA, giving the cytoplasm a mottled appearance.  
4.5 TUNEL staining 
After deparaffinization, the sections were rinsed with 0.1 M PBS, pH 7.4, for 10 min at room 
temperature, treated with 0.3% Triton X-100 in 0.1 M PBS for 15 min at room temperature, 
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and rinsed in 0.1 M PBS. The sections were treated with proteinase K (Sigma) 2 µg/ml in 0.1 
M PBS for 15 min at room temperature. The sections were washed in 0.1 M for 5 min at 
room temperature, and then incubated in 0.25% acetic anhydride (Sigma) in water for 30 
min. After a wash in sterile dH2O for 5 min, the sections were incubated with 
prehybridization solution (0.14M Na cacodylate, 1mM cobalt chloride, 0.03Tris-HCl, pH 7.2) 
for 10 min at RT. The prehybridization solution was then replaced with hybridization solution 
(prehybridization solution plus reaction mixture: 40U/ml deoxynucleotidyl transferase 
enzyme, 0.2mg/ml BSA and 0.5nM/ml digoxigenin-11-dUTP) for 2 hours at 37°C. Sections 
were washed twice for 20 min in 2 x SSC, then washed two more times in 1 x SSC for 15 min 
and 0.5 x SSC for 15 min at room temperature.  Next, sections were washed in 0.1 M Tris 
for 15 min, pH 7.5, incubated in anti-digoxygenin (DIG)-11 (Roche, Nutley, NJ, USA) at 1:1000 
in Tris buffer with 2% BSA for 1.5h, then washed 3 times for 15 m in Tris at room 
temperature. The sections were next immersed in Tris buffer with 0.1M NaCl and 0.05M 
MgCl2, pH 9.5,for 15 min, and incubated in Tris 
-bromo-4-chloro-3-indolyl phosphate (BCIP) (Roche) for 
color development. Sections were rinsed several times in 0.01M Tris buffer with 1 mM EDTA 
and then mounted on glass slides with water-soluble mounting medium. 
4.6 Image Quantitation and Statistical analysis 
Immunostaining was observed under a Nikon Eclipse 80i microscope (Nikon, Japan) and 
images acquired with a Nikon DS high-resolution digital color camera (1280x1024 pixel) 
using NIS-Elements AR 3.0 software. Digital images were analyzed using Ver.3.00 analysis 
program (Nikon).  Percentage of immunostained area (field area of immunostaining/total 
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image area x100) was determined for all the markers studied by averaging several images 
per section that cover all or most of the region of study. All experiments were repeated at 
least twice, with n= 10 animals per group per marker.  All quantitative comparisons were 
performed on sections processed at the same time. 
Single ANOVA statistical analysis was used to assess the significance of the differences in 
anti-GFAP, NF-B, PDI and TUNEL staining reactivity among the animal groups.  A 
one-tailed value of p<0.05 was accepted as significant. 
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Figure legends 
Fig 1a.   Brain sections immunostained for GFAP.  YC = young controls, YM = young 
melatonin-treated, OC = old control, OM = old melatonin-treated. a) Magnification = X40, GP 
= medial globus pallidus., Magnification = X40  
Fig. 1b.   Enlarged aspect of globus pallidus.  Magnification = X200.   Arrows indicate 
activated astrocytes.  
Fig. 1c.   Quantitation of effect of melatonin treatment on GFAP and staining in globus 
pallidus of 4 and 24 month-old mice.  Bars indicate mean of 11-12 animals, ± S.E.M.  *: 
Value for mice treated with melatonin differs from value for corresponding untreated 
control of same age.  #: Old control value differs from that of the young control (p<0.05).  
 
Fig. 2a.   Immunostaining of the globus pallidus for NF-κB.  YC = young control, YM = 
young melatonin，OC = old control, OM = old melatonin.  Magnification = X200 
Fig. 2b.   Quantitation of effect of melatonin treatment on NFkB staining in globus pallidus 
of 4 and 24 month-old mice. Bars indicate mean of 11-12 animals, ± S.E.M. *: Value for mice 
treated with melatonin differs from value for corresponding untreated control of same age.  
#: Old control value differs from that of the young control (p<0.05). 
Fig. 3a.  Effect of melatonin treatment on protein disulfide isomerase (PDI) immunostaining 
of globus pallidus. Magnification = X200. 
 
Fig 3b.   Quantitation in globus pallidus of young and old animals. YC = young control, YM = 
young melatonin，OC = old control, OM = old melatonin. Bars indicate mean of 11-12 
animals, ± S.E.M. *: Value for mice treated with melatonin differs from value for 
corresponding untreated control of same age.  #: Old control value differs from that of the 
young control (p<0.05). 
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Fig. 4a.   Effect of melatonin treatment on Nissl staining of globus pallidus sections of 4 
and 24 month old mice. YC = young control, YM = young melatonin，OC = old control, OM = 
old melatonin.  Magnification = X200.   
Fig. 4b.  Quantitation of Nissl staining. Bars indicate mean of 11-12 animals, ± S.E.M.  *: 
Value for mice treated with melatonin differs from value for corresponding untreated 
control of same age.  #: Old control value differs from that of the young control (p<0.05).  
Fig 5a.   Effect of melatonin treatment on extent of apoptosis in cortex of 4 and 
24 month-old mice as determined by TUNEL staining.  Arrows indicate cells with positive 
TUNEL stain. YC = young control, YM = young melatonin，OC = old control, OM = old 
melatonin.  
Fig. 5b.   Quantitation of TUNEL staining.  Bars indicate mean of 11-12 animals, ± S.E.M.  
*: Value for mice treated with melatonin differs from value for corresponding untreated 
control of same age.  #: Old control value differs from that of the young control (p<0.05). 
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